Publications by authors named "Misa Ashida"
Introduction: High human herpesvirus 8 (HHV-8) seroprevalence has been reported in men who have sex with men (MSM) and are infected with HIV-1. However, it is unclear when they become infected with HHV-8. Thus, we conducted cross-sectional and longitudinal investigations of HHV-8 seroprevalence in HIV-1-infected individuals in Osaka, Japan.
View Article and Find Full Text PDFAn elderly woman with human immunodeficiency virus-1 infection developed short bowel syndrome as a result of extensive intestinal resection. Considering the possibility of poor absorption of antiretroviral drugs (ARVs), therapeutic drug monitoring (TDM) was performed. A single-dose test of 6 ARVs (darunavir, ritonavir, lopinavir, etravirine, maraviroc, and raltegravir) did not provide information on the appropriate ARV, and repeated TDM under continuous antiretroviral therapy resulted in viral suppression below 50 copies/mL, which was considered to be treatment success.
View Article and Find Full Text PDFArticle Synopsis
- Raltegravir (RAL) is an HIV medication that is primarily metabolized by the enzyme UGT1A1, and variations in this gene can influence how the drug works in individuals.
- A study on 114 Japanese HIV-1 patients found that specific gene variations, UGT1A1*6 and UGT1A1*28, occur in around 18% and 13% of patients, respectively, affecting the levels of RAL in their blood.
- Patients with certain gene variations, particularly those homozygous for UGT1A1*6, had significantly higher RAL levels, highlighting the importance of these genetic factors in determining optimal drug concentrations.
Background: Estimates of the interval from HIV-1 infection to disease progression may be affected by selection bias, and data concerning asymptomatic early seroconverters are limited. We examined the interval until disease progression in HIV-1 seroconverters in whom the timing of infection could be estimated within 1 year before diagnosis.
Methods: Subjects included newly diagnosed patients at Osaka National Hospital between 2003 and 2010 who had either (1) symptomatic acute HIV-1 infection with a negative or intermediate reaction on Western blotting and a positive reaction on an HIV RNA test (symptomatic acute group) or (2) a positive reaction on Western blotting at diagnosis and a <1-year interval from the last negative HIV test until the first positive test.